Novartis has joined Shinsei Corporate Investment, Seventure Partners, INCJ and Mitsubishi UFJ Capital in a $13.2m round for the cancer drug developer.

Axonics Modulation Technologies has added more than $20m to a Legend Capital-backed series C round that took the company's total funding past the $100m mark.

The obstetrics care platform developer has received new funding in a round featuring Chemo Group and corporate venturing unit Aurora Health Care Ventures.

Mirexus, a biomaterials spinout of Guelph, will use the funding to support a new production facility.

The antibody replacement technology was co-developed by the California Institute of Technology.

Merck unit M Ventures co-led an $11.5m round for the antibody replacement technology developer with corporate-sponsored firm Legend Capital.

The Manchester spinout is seeking capital to launch its first product, a test that can detect the early-stage onset of an eye disease called age-related macular degeneration.

Existing investor Novo Ventures contributed to a series C round announced alongside Unchained Labs' acquisition of protein measurement device maker Trinean.

Frontier IP has received a 20% stake in Molendotech, a new spinout of Plymouth University that has developed a way to test the purity of water.

The pharmaceutical company has bought diabetes management platform MySugr for an undisclosed sum, two years after its corporate venturing unit backed a $4.8m seed round.